0.9827
Alzamend Neuro Inc stock is traded at $0.9827, with a volume of 106.27K.
It is down -3.66% in the last 24 hours and up +35.54% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.02
Open:
$1.02
24h Volume:
106.27K
Relative Volume:
0.30
Market Cap:
$6.48M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.1469
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
-7.29%
1M Performance:
+35.54%
6M Performance:
-40.80%
1Y Performance:
-89.08%
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALZN
Alzamend Neuro Inc
|
0.9827 | 6.48M | 0 | -5.85M | -8.00M | -6.6877 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update - Defense World
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
Alzamend neuro director William Horne buys $3,285 in common stock By Investing.com - Investing.com Australia
Alzamend neuro director William Horne buys $3,285 in common stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock - Investing.com India
Alzamend Neuro director Milton Ault buys $2,968 in company stock By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital - The Manila Times
Major Breakthrough: New Alzheimer's Drug Advances to Phase II at Top Hospital - Stock Titan
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock By Investing.com - Investing.com Australia
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock - Investing.com
Alzamend Neuro director William B. Horne purchases $4,891 in shares - Investing.com India
Alzamend Neuro director William B. Horne purchases $4,891 in shares By Investing.com - Investing.com UK
Alzamend Neuro director William B. Horne buys $4,851 in stock - Investing.com India
Alzamend Neuro director William B. Horne buys $4,851 in stock By Investing.com - Investing.com South Africa
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares - Investing.com Australia
Alzamend Neuro director Milton C. Ault III acquires $4,810 in shares By Investing.com - Investing.com South Africa
Alzamend Neuro, Inc. Plans Phase II Clinical Study of AL001 in Major Depressive Disorder to Compare Lithium Delivery with Marketed Products - Nasdaq
Alzamend Neuro Announces Initiation Date of Phase II - GlobeNewswire
Major Depression Breakthrough: New Lithium Treatment Heads to Phase II at Top Hospital - StockTitan
Alzamend Neuro (ALZN) Projected to Post Earnings on Monday - Defense World
Alzamend Neuro director Milton Ault buys $68 in stock By Investing.com - Investing.com Australia
Alzamend Neuro director Milton Ault buys $68 in stock - Investing.com
Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Rises By 332.2% - Defense World
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline - Investing.com Australia
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro stock hits 52-week low at $0.68 amid sharp decline By Investing.com - Investing.com South Africa
Alzamend Neuro plans mid-stage study of its therapy for PTSD in fourth-quarter 2025 - Marketscreener.com
Major PTSD Breakthrough: New Lithium Treatment Heads to Phase II Trial at Top Hospital - StockTitan
EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits - Benzinga
Alzamend Neuro Inc. (ALZN) reports earnings - Quartz
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 33.0% in February - Defense World
Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital - Marketscreener.com
Alzamend Neuro announces initiation date of Phase II trial of AL001 - TipRanks
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Announces Phase II Clinical Study of AL001 for Bipolar Disorder Expected to Start in Q3 2025 - Nasdaq
Alzamend Neuro Plans Phase II Trial for Advanced Lithium Treatment in Bipolar Disorder | ALZN Stock News - StockTitan
Alzamend Neuro Announces Bylaws Amendment and New Stock Series By Investing.com - Investing.com South Africa
Alzamend Neuro Announces Bylaws Amendment and New Stock Series - Investing.com
Alzamend Neuro stock hits 52-week low at $0.81 amid sharp decline - Investing.com Australia
Alzamend Neuro inks deal for equity securities sale By Investing.com - Investing.com South Africa
Alzamend Neuro inks deal for equity securities sale - Investing.com
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):